Sale!

GLUCORYL MD FORTE 10/1/1000 TABLET

Original price was: ₹160.00.Current price is: ₹136.00.

Dapagliflozin 10mg + Glimepiride 1mg + Metformin 1000mg

Alkem Laboratories Ltd

🩺 Product Overview

Dapagliflozin 10 mg, Glimepiride 1 mg, and Metformin 1000 mgβ€”this tablet addresses multiple pathophysiological aspects of T2DM, offering enhanced glycemic control and improved patient adherence.

πŸ’Š Composition

  • Dapagliflozin (10 mg): A Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, promoting glucose excretion through urine.
  • Glimepiride (1 mg): A sulfonylurea that stimulates insulin release from pancreatic Ξ²-cells, enhancing insulin secretion.
  • Metformin (1000 mg): A biguanide that decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues.

βš™ Mechanism of Action

  • Dapagliflozin: Inhibits SGLT2 in the renal proximal tubules, leading to increased urinary glucose excretion and a reduction in blood glucose levels.
  • Glimepiride: Binds to ATP-sensitive potassium channels on pancreatic Ξ²-cells, causing depolarization and subsequent insulin release.
  • Metformin: Suppresses hepatic glucose production and enhances insulin sensitivity, facilitating improved glucose uptake by peripheral tissues.

βœ… Indications

DAPA-GM-MET 10/1/1000 Tablet is indicated for:

  • Adults with Type 2 Diabetes Mellitus inadequately controlled by diet and exercise alone.
  • Patients requiring combination therapy with Metformin and Glimepiride.
  • Individuals seeking to minimize pill burden while achieving optimal glycemic control.

πŸ“ˆ Clinical Benefits

  • Enhanced Glycemic Control: Targets multiple mechanisms to effectively lower blood glucose levels.
  • Reduced Risk of Hypoglycemia: The combination of agents helps mitigate the risk of low blood sugar.
  • Cardiovascular and Renal Protection: Dapagliflozin offers additional benefits in heart failure and chronic kidney disease.
  • Weight Neutrality: Unlike many anti-diabetic medications, this combination may support weight management.
  • Convenience: Combines three medications into a single tablet, improving patient adherence.

πŸ“Š Efficacy

A Phase III, open-label, randomized clinical study conducted in India demonstrated that the fixed-dose combination of Dapagliflozin, Glimepiride, and Metformin extended-release tablets significantly reduced HbA1c levels compared to dual therapy with Glimepiride and Metformin prolonged-release tablets. The study reported a mean reduction in HbA1c of -1.98% Β± 1.01% in the triple therapy group, compared to -1.64% Β± 0.86% in the dual therapy group (p = 0.0047) .

⚠ Precautions

  • Renal Function: Regular monitoring of renal function is advised, as Dapagliflozin is contraindicated in patients with severe renal impairment.
  • Hypoglycemia: Caution is required when used with other antidiabetic agents that may cause hypoglycemia.
  • Lactic Acidosis: A rare but serious side effect associated with Metformin; avoid in patients with conditions that predispose to acidosis.
  • Volume Depletion: Dapagliflozin may cause diuresis; ensure adequate hydration.

πŸ’Š Dosage and Administration

  • Dosage: One tablet once daily with meals, preferably with breakfast.
  • Administration: Swallow the tablet whole with a glass of water; do not chew or crush.
  • Adjustment: Dosage may be adjusted based on individual patient response and tolerability.

🧾 Side Effects

Common side effects may include:

  • Metformin: Gastrointestinal disturbances such as nausea, vomiting, and diarrhea.
  • Glimepiride: Hypoglycemia, dizziness, and headache.
  • Dapagliflozin: Urinary tract infections, genital infections, and increased urination.

Serious but rare side effects include:

  • Lactic Acidosis: Symptoms include muscle pain, respiratory distress, and fatigue.
  • Severe Hypoglycemia: Symptoms include confusion, sweating, and rapid heartbeat.

πŸ§ͺ Drug Interactions

  • Alcohol: May potentiate the effect of Metformin and increase the risk of lactic acidosis.
  • Diuretics: May increase the risk of dehydration and hypotension when used with Dapagliflozin.
  • Insulin and Insulin Secretagogues: May increase the risk of hypoglycemia.

πŸ§‘β€βš• Use in Special Populations

  • Pregnancy and Lactation: Not recommended; consult a healthcare provider before use.
  • Geriatric Patients: Use with caution; monitor renal function closely.
  • Pediatric Patients: Safety and efficacy have not been established.

πŸ—„ Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

 

Tablet

Reviews

There are no reviews yet.

Be the first to review “GLUCORYL MD FORTE 10/1/1000 TABLET”

Your email address will not be published. Required fields are marked *

Shopping Cart
Scroll to Top